U.S. Infrastructure Stock News

NYSE:AMG
NYSE:AMGCapital Markets

Affiliated Managers Group (AMG) Could Be 7% Below Fair Value After Recent Momentum

Affiliated Managers Group (AMG) stock continues to draw interest after recent trading, with shares closing at US$356.27 and posting returns over the past week, month, past 3 months, and year that some investors are watching closely. See our latest analysis for Affiliated Managers Group. Against this backdrop, Affiliated Managers Group's recent share price pullback of 0.96% over the last trading day comes after steady momentum, with a 90 day share price return of 24.43% and a 1 year total...
NasdaqGS:LPLA
NasdaqGS:LPLACapital Markets

LPL Financial Holdings (LPLA) Could Be 28% Undervalued As Russell Value Adds Stir Debate

Index additions put LPL Financial Holdings back in the spotlight LPL Financial Holdings (LPLA) has been added to several Russell value benchmarks, a shift that is drawing fresh attention to the stock and intensifying debate over what investors should pay for it. The company now sits in the Russell 3000 Value, Russell 1000 Value, Russell Midcap Value, Russell 3000E Value, and Russell Small Cap Comp Value benchmarks. This places LPL Financial Holdings in front of a broader group of index...
NasdaqGM:NAMS
NasdaqGM:NAMSBiotechs

Did NewAmsterdam’s (NAMS) Alzheimer’s Biomarker Signal Just Recast Obicetrapib’s Dual-Disease Investment Narrative?

NewAmsterdam Pharma announced that it will present data at the 2026 Alzheimer’s Association International Conference in London on obicetrapib, an oral, low-dose CETP inhibitor, showing statistically significant effects on Alzheimer’s disease biomarkers in cardiovascular patients from the Phase 3 BROADWAY trial. The analyses highlight reduced p-tau217 levels, particularly in ApoE4 carriers, hinting at a potential role for obicetrapib in early Alzheimer’s disease prevention alongside its...
NasdaqGS:BCRX
NasdaqGS:BCRXBiotechs

Is BioCryst (BCRX) Trading Internal Discovery for a More Durable Rare-Disease Innovation Model?

In late June 2026, BioCryst Pharmaceuticals said it would discontinue its internal discovery programs and close its Birmingham, Alabama Discovery Center of Excellence by the end of 2026, shifting its rare disease pipeline development toward external innovation and partnerships. This move marks a major change in how BioCryst sources future drug candidates, trading in-house research infrastructure for a more flexible, partner-driven model that could reshape its long-term pipeline mix. Next,...
NYSE:DDS
NYSE:DDSMultiline Retail

Dillard's (DDS) On Strong First Quarter Results Is The Stock A Bargain Or Priced Right

Why Dillard's Stock Is Back in Focus Dillard's (DDS) is drawing investor attention after first quarter results showed firmer sales and margins, supported by healthy consumer demand, refreshed merchandise assortments, and ongoing investment in its omnichannel retail model. See our latest analysis for Dillard's. Dillard's share price has cooled after its recent update, with the stock down 15.6% over the past month and 18.9% year to date, even though the 1 year total shareholder return is 24.4%...
NYSE:MIR
NYSE:MIRElectronic

Does Mirion Technologies’ (MIR) Expanded Russell Index Footprint Reframe Its Long‑Term Investor Base Narrative?

On 27 June 2026, Mirion Technologies, Inc. (NYSE:MIR) was added to a range of Russell indices, including Russell 3000 and Russell 2000 value and defensive benchmarks, broadening its index footprint after the reconstitution. This broad inclusion across value, growth, and defensive small-cap indices places Mirion on the radar of a wider base of index-tracking and quantitatively driven investors. We’ll now examine how Mirion’s addition to multiple Russell value and defensive indices may...
NasdaqGS:GRAB
NasdaqGS:GRABTransportation

Grab Stock And 2 Penny Stocks With Stronger Balance Sheets

Penny stocks often attract attention for their low share prices, but the real interest right now is in companies that pair that low entry point with healthier balance sheets and more disciplined financial profiles. With inflation trends uneven across regions, central banks watching every data release, and energy prices feeding into bond yields and consumer budgets, many investors are looking at ways to get exposure to smaller companies while keeping an eye on risk. The Financially Fit Penny...
NasdaqGS:ZION
NasdaqGS:ZIONBanks

How Investors Are Reacting To Zions Bancorporation (ZION) Joining Russell’s Defensive and Value-Defensive Indices

In late June 2026, Zions Bancorporation, National Association (NasdaqGS: ZION) was added to both the Russell 1000 Defensive Index and the Russell 1000 Value-Defensive Index, reflecting its classification among more defensive, value-oriented U.S. large-cap banks. This dual index inclusion could increase Zions’ visibility with institutional investors that track or benchmark against Russell’s defensive indices and may influence how the market frames its risk profile and income-oriented...
NasdaqGS:DBX
NasdaqGS:DBXSoftware

How Dropbox’s Shift Into Value-Defensive Indices Will Impact Dropbox (DBX) Investors

On 27 June 2026, Dropbox was removed from several Russell growth benchmarks and simultaneously added to the Russell 1000 Value-Defensive and Russell 1000 Defensive indices, reflecting a formal style shift in how the stock is classified by index providers. This reclassification could influence how quantitative and index-tracking investors view Dropbox, potentially reshaping perceptions of the company from a growth-oriented software name toward a more value and defensively positioned...
NasdaqGS:CPB
NasdaqGS:CPBFood

Mondelez Stock And 2 Defensive Staples For Rising Oil And Inflation

With bond yields climbing and oil back above $80, investors are again being reminded how quickly macro shocks can hit portfolios. Consumer staples stocks, which sell everyday essentials across markets like the US, UK, Canada, Australia, and New Zealand, can sometimes offer a different risk profile to more cyclical areas when volatility picks up, although that is not guaranteed. This article focuses on our Defensive Consumer Staples screener, built around the latest US Iran tensions and...
NYSE:POR
NYSE:PORElectric Utilities

Portland General Electric (POR) Wins New Data Center Rates, Is The Stock Fully Valued?

The Oregon Public Utility Commission has approved a new POWER Act rate structure for Portland General Electric (POR), raising data center tariffs by 29% while lowering charges for residential and other customers across its service territory. See our latest analysis for Portland General Electric. At a share price of $52.24, Portland General Electric has seen momentum soften recently, with the 90 day share price return declining 3.65%, even as the year to date share price return is 7.80% and...
NasdaqGS:EXPE
NasdaqGS:EXPEHospitality

How Investors Are Reacting To Expedia Group (EXPE) Loyalty Revamp Amid Rising Oil-Driven Travel Costs

Expedia Group recently announced it will report its second quarter 2026 results for the period ended June 30, 2026, via an earnings release and webcast on August 5, 2026, with materials available through its investor relations website. Ahead of that update, the company is adjusting its One Key loyalty program while the broader online travel sector reacts to renewed Middle East tensions and higher oil prices that may influence travel costs and customer behavior. We’ll now explore how these...
NasdaqCM:SLS
NasdaqCM:SLSBiotechs

Galinpepimut-S REGAL Readout and Deal Chatter Might Change The Case For Investing In SELLAS (SLS)

In recent comments, SELLAS Life Sciences Group CEO Angelos M. Stergiou addressed concerns about perceived delays in the pivotal Phase 3 REGAL trial for Galinpepimut-S in acute myeloid leukemia, clarifying that there is still no approved maintenance therapy for patients in a second complete remission and that 78 of the 80 required events for final analysis have now occurred. At the same time, a small new position reported by CoreCap Advisors and updated change-of-control terms have fueled...
NasdaqGS:ARWR
NasdaqGS:ARWRBiotechs

Arrowhead Pharmaceuticals (ARWR) Is Up 6.6% After Russell Index Upgrade Has The Bull Case Changed?

On 27 June 2026, Arrowhead Pharmaceuticals, Inc. was removed from several Russell 2000 benchmarks and simultaneously added to larger Russell indices including the Russell 1000, Midcap, and multiple growth and value sub-benchmarks, reflecting a reclassification of its market-cap and style profile. This broad reshuffling across Russell indices can meaningfully influence trading volumes and ownership, as index-tracking funds and quantitative managers adjust their positions in response. Next,...
NasdaqGS:AMZN
NasdaqGS:AMZNMultiline Retail

This Week In E-Commerce - Shopify's Q2 2026 Financial Results Announcement Insights

Shopify Inc. is set to release its financial results for the second quarter of 2026, with the announcement scheduled for August 5 before market open. A conference call hosted by Shopify's management will follow to discuss the results, available via webcast on the company's Investor Relations website. This announcement aligns with Shopify's ongoing role as a provider of essential internet infrastructure for commerce, supporting millions of businesses worldwide. The upcoming financial...
NYSE:GEO
NYSE:GEOCommercial Services

How GEO Group’s Shift From Russell Growth To Value Indices Has Changed Its Investment Story (GEO)

On 27 June 2026, GEO Group was removed from multiple Russell growth benchmarks and simultaneously added to several Russell value indices, marking a significant style reclassification within the Russell index family. This broad shift from growth to value benchmarks is important because it can alter which index-tracking funds hold GEO shares and how much capital is passively allocated to the stock. We’ll now examine how GEO’s move from Russell growth to value indices could reshape the...
NasdaqGS:GILD
NasdaqGS:GILDBiotechs

Gilead (GILD) Stock Looks Below Fair Value But Earnings Already Look Priced In

Gilead Sciences stock has delivered a strong 5 year run, yet the valuation checks point to a mixed picture rather than a clear bargain or an obvious overvaluation at today’s price. Gilead Sciences has returned about 140.0% over the past 5 years, which puts more focus on whether today’s share price already reflects much of that progress. Recent regulatory wins for Trodelvy in breast cancer and ongoing HIV pipeline progress can support optimistic expectations for future cash flows. However,...
NasdaqGS:BOKF
NasdaqGS:BOKFBanks

Should BOK Financial’s (BOKF) Russell 1000 Dynamic Exit Prompt Portfolio Rebalancing by Investors?

In late June 2026, BOK Financial Corporation was removed from the Russell 1000 Dynamic Index, altering its presence in a widely followed benchmark. This index removal may influence how index-tracking funds and benchmark-conscious investors treat BOK Financial within diversified portfolios. We’ll now explore how the loss of Russell 1000 Dynamic Index inclusion could influence BOK Financial’s existing investment narrative and outlook. Invest in the nuclear renaissance through our list of 89...
NYSE:NMAX
NYSE:NMAXMedia

Newsmax (NMAX) Stock May Be A Bargain On Cash Flow Alone

Newsmax stock sits at an unusual valuation crossroads, with the intrinsic value estimate from a Discounted Cash Flow (DCF) model pointing to a sizeable gap below the current share price while traditional market multiples suggest the stock already trades on the expensive side. Over the past year, Newsmax shares have fallen 45.4%, which means the current valuation is being assessed after a substantial pullback. For Newsmax, expectations around the durability of future cash flows can support...
NasdaqGS:NTRA
NasdaqGS:NTRABiotechs

How New Signatera Colorectal Data and Trial Deals Could Shape Natera’s (NTRA) Long-Term Narrative

Natera recently reported that Monica Bertagnolli resigned from its board due to her new role at the National Academy of Medicine and highlighted fresh JAMA Oncology and ESMO GI data showing its Signatera MRD test can help guide adjuvant chemotherapy decisions and prognostication in resected colorectal liver metastases, while also announcing new Prospera and Signatera clinical trial partnerships. This combination of strengthened clinical evidence and expanded trial integrations for Natera’s...
NYSE:STZ
NYSE:STZBeverage

Constellation Brands (STZ) Beat On Earnings, Is The Stock Still Cheap?

Constellation Brands (STZ) has drawn fresh attention after first quarter results showed lower sales but higher net income and earnings per share, alongside continued buybacks, a quarterly dividend and new index inclusions. See our latest analysis for Constellation Brands. Despite the solid first quarter earnings beat and continued buybacks, Constellation Brands’ share price has fallen 20.1% over the past three months to US$130.34, and the 1 year total shareholder return has declined 20.8%...
NYSE:BHE
NYSE:BHEElectronic

Will Benchmark Electronics’ New Russell Index Placements Subtly Reframe Its Growth Narrative And Risk Profile (BHE)?

In late June 2026, Benchmark Electronics, Inc. (NYSE:BHE) was added to multiple Russell growth and small-cap indices, including the Russell 2000 Growth, Russell 2500 Growth, and Russell 3000 Growth benchmarks. This cluster of index inclusions may broaden the company’s shareholder base, as index-tracking funds and mandates adjust their holdings to include the stock. Next, we’ll examine how Benchmark’s inclusion in several Russell growth indices may influence its existing investment narrative...
NasdaqCM:RIOT
NasdaqCM:RIOTSoftware

Riot Platforms (RIOT) Stock May Be Fully Priced As AI Data Center Optimism Builds

Riot Platforms has delivered a strong 72.3% return over the past year, yet the stock now sits in territory where the broader valuation checks suggest it is expensive rather than a clear bargain. Riot Platforms' 72.3% gain over 1 year has rewarded existing shareholders, but it also raises the bar for future returns at the current price. Hopes around growth in AI focused data centers can support sentiment, while concerns about a stretched valuation and ongoing capital needs for new facilities...
NYSEAM:UEC
NYSEAM:UECOil and Gas

Uranium Energy (UEC) Stock Looks Fully Valued As ISR Expansion Faces Challenges

Uranium Energy stock has delivered a very strong 364.0% return over the past 5 years, yet its current valuation checks and premium market multiples suggest the shares are no longer an obvious bargain. A roughly 5 year return of 364.0% points to a stock that has already priced in a lot of optimism about Uranium Energy's future cash generation. The push into U.S. in situ recovery production and a proposed uranium refining and conversion facility can support long term earnings potential, while...